Product Description
Clexio is developing CLE-400, a topical gel formulation containing a non-opioid, non-steroid, analgesic compound, to treat patients suffering from peripheral neuropathic pain. CLE-400 is a new investigational drug that has not been approved for commercial distribution. (Sourced from: https://www.clexio.com/pipeline/cle-400-pain/)
Mechanisms of Action: ADRA2 Agonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clexio Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Back Pain|Chronic Pain|Pruritus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CLE400-NP-201 | P2 |
Completed |
Pruritus|Chronic Pain|Back Pain |
2024-11-06 |